Evidence map›Paper›PMID 37009042›Full record

ArticleFood science and biotechnology2023

Bukyung Kim, Hak Sung Lee, Hye-Jin Kim, Hyolynn Lee, In-Young Lee, Soyoung Ock, Sukyoung Kwon, Sang-Soo Kang, Youngsik Choi

Open access · hybridFull text read
In one paragraph

Article in Food science and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. The metabolic effect ofFrontiers in nutrition · 2023
    Pooled it
  3. Observational
  4. Review
  5. Review
  6. Observational
  7. Article
  8. Efficacy ofMetabolism open · 2025
    Review
  9. Plants (Basel, Switzerland) · 2025
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Bukyung Kim *Department of Internal Medicine, Kosin University School of Medicine, Busan, Korea.ORCID 0000-0001-7845-4377
Hak Sung Lee *Natural Product Research Team 2, Skin & Natural Products Lab., Kolmar BNH Co., Ltd., Seoul, Korea.
Hye-Jin KimNatural Product Research Team 2, Skin & Natural Products Lab., Kolmar BNH Co., Ltd., Seoul, Korea.
Hyolynn LeeDepartment of Internal Medicine, Kosin University School of Medicine, Busan, Korea.
In-Young LeeDepartment of Internal Medicine, Kosin University School of Medicine, Busan, Korea.
Soyoung OckDepartment of Internal Medicine, Kosin University School of Medicine, Busan, Korea.
Sukyoung KwonDepartment of Internal Medicine, Kosin University School of Medicine, Busan, Korea.
Sang-Soo KangDepartment of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
Youngsik ChoiDepartment of Internal Medicine, Kosin University School of Medicine, Busan, Korea.
Kosin University · KRKolmar Korea (South Korea) · KRGyeongsang National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was performed to investigate the effects of bitter melon extract (BME) on glucose metabolism, insulin resistance, and various metabolic parameters of participants with prediabetes. A 12-week randomized placebo-controlled clinical study was conducted with prediabetic patients. A total of 76 participants were randomly assigned to initiate the study. In the final analysis, 33 and 32 subjects were included in the BME and placebo groups, respectively. Results showed that 75 g oral glucose tolerance test (OGTT) blood glucose level decreased in BME group after 12 weeks. The glucose level after 30 min of glucose ingestion decreased significantly. The glucagon level in the BME group after 12 weeks significantly decreased 120 min after 75 g OGTT. These results suggested that bitter melon exhibits glucose-lowering effects through suppression of glucagon levels in people with prediabetes.

Indexed as

Bitter melonGlucoseMomordica charantiaPrediabetes

Identifiers

PMID37009042
PMCPMC10050654
OpenAlexW4311497235

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.